Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 09 February 2018


Renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.



Learn about the complex factors influencing development of obesity.

+ 4 more



See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000254
Orphan designation No
Date First Approved 28-01-2000
Type Medicinal product subject to medical prescription
Marketing authorisation holder Genzyme Europe B.V.